Clinical Trials Logo

Clinical Trial Summary

This study is designed as a combined Phase II/III, randomized, open label, multicenter, prospective comparative study of sirolimus plus prednisone versus sirolimus/calcineurin-inhibitor plus prednisone for the treatment of chronic GVHD. Patients will be stratified by transplant center and will be randomized to an experimental arm of one of the two pre-specified experimental arms (sirolimus + prednisone or the comparator arm of sirolimus + calcineurin inhibitor + prednisone) in a 1:1 ratio.


Clinical Trial Description

Background: Chronic GVHD is a medical condition that can become very serious. Chronic GVHD is a common development after allogeneic transplant that occurs when the donor cells attack and damage tissues. The primary purpose of this study is to compare treatment regimens that contain sirolimus without a calcineurin inhibitor to a comparator regimen of sirolimus with a calcineurin inhibitor and evaluate how well chronic GVHD responds to treatment. The combinations of medications in this study are:

- Sirolimus + calcineurin inhibitor + prednisone

- Sirolimus + prednisone

The goal is to select a treatment regimen for further comparison in the Phase III trial.

Design Narrative: The intent is to enroll subjects at the start of initial therapy for chronic GVHD, or before their chronic GVHD is refractory to glucocorticoid therapy, or is chronically dependent upon glucocorticoid therapy and multiple secondary systemic immunosuppressive agents. Patients will be stratified by transplant center and will be randomized to one of two arms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01106833
Study type Interventional
Source Medical College of Wisconsin
Contact
Status Completed
Phase Phase 2/Phase 3
Start date April 2010
Completion date June 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01937468 - Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Phase 1
Active, not recruiting NCT04294641 - Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease Phase 2
Recruiting NCT05502783 - Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias Phase 2
Enrolling by invitation NCT05509582 - Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias Phase 2
Not yet recruiting NCT06458127 - Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease N/A
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Recruiting NCT04146207 - SHR0302 and Steroid as First Line Therapy for Chronic GVHD Early Phase 1